PharmaEssentia and AOP Orphan Receive EU Approval of Besremi(T...
BURLINGTON, Mass., Feb. 22, 2019 /PRNewswire-AsiaNet/-- PharmaEssentia today announced that the European Commission (EC) has approved Besremi(R) (ropeginterferon alfa-2b, P1101) as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. The European market author...
Authors: LATEST ASIANET NEWS RELEASES